
Pierre Fontana

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7921200/publications.pdf Version: 2024-02-01



DIEDDE FONTANA

#	Article	IF	CITATIONS
1	Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort. Blood Advances, 2022, 6, 2884-2892.	5.2	10
2	<i>ABO</i> O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia. Blood, 2022, 140, 274-284.	1.4	9
3	Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study. Frontiers in Cardiovascular Medicine, 2022, 9, 817826.	2.4	10
4	Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation. Clinical Pharmacology and Therapeutics, 2022, 112, 353-363.	4.7	5
5	Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVIDâ€19: The Swiss COVIDâ€HEP randomized clinical trial. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	18
6	SARS-CoV-2 Infection in Patients with a History of VITT. New England Journal of Medicine, 2022, 387, 88-90.	27.0	7
7	Prothrombinase-Induced Clotting Time to Measure Drug Concentrations of Rivaroxaban, Apixaban, and Edoxaban in Clinical Practice: A Cross-Sectional Study. Life, 2022, 12, 1027.	2.4	1
8	Highly impaired platelet ultrastructure in two families with novel <i>IKZF5</i> variants. Platelets, 2021, 32, 492-497.	2.3	1
9	A Unique Case of Acquired Hemophilia A Presenting with Transient Ischemic Attack. Acta Haematologica, 2021, 144, 88-90.	1.4	1
10	A novel homozygous <i>GFI1B</i> variant in 2 sisters with thrombocytopenia and severe bleeding tendency. Platelets, 2021, 32, 701-704.	2.3	0
11	Mixing Drugs and Genetics: A Complex Hemorrhagic Cocktail. American Journal of Medicine, 2021, 134, e211-e212.	1.5	3
12	Estimating the risk thresholds used by guidelines to recommend postpartum thromboprophylaxis. Journal of Thrombosis and Haemostasis, 2021, 19, 452-459.	3.8	15
13	Methods to Investigate miRNA Function: Focus on Platelet Reactivity. Thrombosis and Haemostasis, 2021, 121, 409-421.	3.4	18
14	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 1364-1371.	3.8	19
15	COVIDâ€19 patients often show highâ€titer nonâ€plateletâ€activating antiâ€PF4/heparin IgG antibodies. Journal of Thrombosis and Haemostasis, 2021, 19, 1294-1298.	3.8	62
16	An Ex Vivo and In Silico Study Providing Insights into the Interplay of Circulating miRNAs Level, Platelet Reactivity and Thrombin Generation: Looking beyond Traditional Pharmacogenetics. Journal of Personalized Medicine, 2021, 11, 323.	2.5	5
17	Proteomics: A Tool to Study Platelet Function. International Journal of Molecular Sciences, 2021, 22, 4776.	4.1	12
18	Platelet-induced cell signaling during liver regeneration. British Journal of Surgery, 2021, 108, .	0.3	0

#	Article	IF	CITATIONS
19	miR-204-5p and Platelet Function Regulation: Insight into a Mechanism Mediated by CDC42 and GPIIbIIIa. Thrombosis and Haemostasis, 2021, 121, 1206-1219.	3.4	6
20	A universal antiâ€Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation. British Journal of Haematology, 2021, 193, 1203-1212.	2.5	24
21	Accuracy of the STA®-Liquid anti-Xa assay in clinical practice: results from a large cross-sectional study in Switzerland. , 2021, 41, .		0
22	A universal anti-Xa assay for the determination of rivaroxaban, apixaban, and edoxaban drug levels: development, diagnostic accuracy, and external validation. , 2021, 41, .		0
23	Do miRNAs Have a Role in Platelet Function Regulation?. Hamostaseologie, 2021, 41, 217-224.	1.9	4
24	Insight into the role of miR-223-3p in regulating platelet reactivity. , 2021, 41, .		0
25	Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. Blood, 2021, 138, 1269-1277.	1.4	102
26	Diagnosing Inherited Platelet Disorders: Modalities and Consequences. Hamostaseologie, 2021, 41, 475-488.	1.9	3
27	Drug-Drug Interactions with Direct Oral Anticoagulants: Practical Recommendations for Clinicians. American Journal of Medicine, 2021, 134, 939-942.	1.5	13
28	Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements. Frontiers in Cardiovascular Medicine, 2021, 8, 717939.	2.4	10
29	New Inhibitors in the Ageing Population: A retrospective, observational, cohort study of new inhibitors in older people with haemophilia. Thrombosis and Haemostasis, 2021, , .	3.4	0
30	The Deglycosylated Form of 1E12, a Monoclonal Anti-PF4 IgG, Strongly Inhibits Antibody-Triggered Cellular Activation in Vaccine-Induced Thrombotic Thrombocytopenia, and Is a Potential New Treatment for Vĺ1Ï,,Ï,,. Blood, 2021, 138, 582-582.	1.4	5
31	Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 203-210.	3.0	69
32	An unusual thrombus location in a Heartmate 3 TM device with fatal outcome. Perfusion (United Kingdom), 2020, 35, 442-446.	1.0	4
33	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. Journal of Thrombosis and Haemostasis, 2020, 18, 732-739.	3.8	64
34	Structure and function of the ubiquitinâ€proteasome system in platelets. Journal of Thrombosis and Haemostasis, 2020, 18, 771-780.	3.8	27
35	Real-life evaluation of an automated immunoassay for diagnosis of heparin-induced thrombocytopenia. Thrombosis Research, 2020, 196, 400-403.	1.7	5
36	Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. Blood, 2020, 136, 1956-1967.	1.4	34

#	Article	IF	CITATIONS
37	Studies on hemostasis in COVIDâ€19 deserve careful reporting of the laboratory methods, their significance, and their limitations. Journal of Thrombosis and Haemostasis, 2020, 18, 3121-3124.	3.8	16
38	Ticagrelor causes false-negative functional tests for heparin-induced thrombocytopenia. Blood, 2020, 135, 875-878.	1.4	11
39	Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. Clinical Pharmacology and Therapeutics, 2020, 108, 1067-1077.	4.7	32
40	MicroRNA-126 is a regulator of platelet-supported thrombin generation. Platelets, 2020, 31, 746-755.	2.3	17
41	Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. Critical Care, 2020, 24, 364.	5.8	118
42	Contribution of exome sequencing to the identification of genes involved in the response to clopidogrel in cardiovascular patients. Journal of Thrombosis and Haemostasis, 2020, 18, 1425-1434.	3.8	2
43	Diagnosis of Inherited Platelet Disorders on a Blood Smear. Journal of Clinical Medicine, 2020, 9, 539.	2.4	30
44	Platelet Function Test Use for Patients with Coronary Artery Disease in the Early 2020s. Journal of Clinical Medicine, 2020, 9, 194.	2.4	12
45	Diagnosis and management of heparin-induced thrombocytopenia. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 291-310.	1.4	45
46	Platelet Interactions with Liver Sinusoidal Endothelial Cells and Hepatic Stellate Cells Lead to Hepatocyte Proliferation. Cells, 2020, 9, 1243.	4.1	19
47	Platelet Transforming Growth Factor-β1 Induces Liver Sinusoidal Endothelial Cells to Secrete Interleukin-6. Cells, 2020, 9, 1311.	4.1	7
48	Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland. Swiss Medical Weekly, 2020, 150, w20210.	1.6	9
49	Thromboprophylaxis and laboratory monitoring for in-hospital patients with Covid-19 - a Swiss consensus statement by the Working Party Hemostasis. Swiss Medical Weekly, 2020, 150, w20247.	1.6	77
50	Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines. Swiss Medical Weekly, 2020, 150, w20301.	1.6	39
51	Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab. Swiss Medical Weekly, 2020, 150, w20422.	1.6	15
52	Obstetrical and postpartum complications in women with hereditary fibrinogen disorders: A systematic literature review. Haemophilia, 2019, 25, 747-754.	2.1	15
53	Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra [®]): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP). Haemophilia, 2019, 25, 731-737.	2.1	43
54	Platelets and Plateletâ€Derived Extracellular Vesicles in Liver Physiology and Disease. Hepatology Communications, 2019, 3, 855-866.	4.3	25

#	Article	IF	CITATIONS
55	Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants. Clinical Pharmacokinetics, 2019, 58, 1517-1532.	3.5	6
56	Platelet Function Testing or Genotyping. JACC: Cardiovascular Interventions, 2019, 12, 1867-1868.	2.9	1
57	Functional Validation of microRNA-126-3p as a Platelet Reactivity Regulator Using Human Haematopoietic Stem Cells. Thrombosis and Haemostasis, 2019, 119, 254-263.	3.4	32
58	Outcome of an enhanced diagnostic pipeline for patients suspected of inherited thrombocytopenia. British Journal of Haematology, 2019, 186, 373-376.	2.5	12
59	Detection of Anti-Cardiolipin and Anti-β2glycoprotein I Antibodies Differs between Platforms without Influence on Association with Clinical Symptoms. Thrombosis and Haemostasis, 2019, 119, 797-806.	3.4	30
60	Selective inhibition of Panx1 channels decreases hemostasis and thrombosis in vivo. Thrombosis Research, 2019, 183, 56-62.	1.7	12
61	Management of antiplatelet therapy for non-elective invasive procedures or bleeding complications: Proposals from the French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Thrombosis and Haemostasis (GFHT), in collaboration with the French Society for Anaesthesia and Intensive Care (SFAR). Archives of Cardiovascular Diseases. 2019. 112. 199-216.	1.6	20
62	Management of antiplatelet therapy for non elective invasive procedures of bleeding complications: proposals from the French working group on perioperative haemostasis (GIHP), in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR). Anaesthesia, Critical Care & amp; Pain Medicine, 2019, 38, 289-302.	1.4	25
63	A high glucose level is associated with decreased aspirin-mediated acetylation of platelet cyclooxygenase (COX)-1 at serine 529: A pilot study. Journal of Proteomics, 2019, 192, 258-266.	2.4	9
64	Thrombin generation and fibrin clot structure after vitamin D supplementation. Endocrine Connections, 2019, 8, 1447-1454.	1.9	19
65	Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients?. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2018, 6, 280-281.	1.6	0
66	Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites. Clinical Pharmacokinetics, 2018, 57, 1347-1354.	3.5	52
67	Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (CIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR). Archives of Cardiovascular Diseases, 2018, 111, 210-223.	1.6	22
68	Evaluation of recombinant factor VIIa, tranexamic acid and desmopressin to reduce prasugrel-related bleeding. European Journal of Anaesthesiology, 2018, 35, 208-214.	1.7	10
69	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). American Heart Journal, 2018, 198, 152-159.	2.7	24
70	Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR). Anaesthesia, Critical Care & amp; Pain Medicine, 2018, 37, 379-389.	1.4	25
71	Management of bleeding and emergency invasive procedures in patients on dabigatran: Updated guidelines from the French Working Group on Perioperative Haemostasis (GIHP) –ÂSeptember 2016. Anaesthesia, Critical Care & Pain Medicine, 2018, 37, 391-399.	1.4	36
72	Position du GIHP sur les tests viscoélastiquesÂ: quelle place pour quelle indication en situation hémorragique�. Anesthésie & Réanimation, 2018, 4, 452-464.	0.1	0

#	Article	IF	CITATIONS
73	Platelet reactivity in stable cardiovascular patients with chronic kidney disease. Platelets, 2018, 29, 455-462.	2.3	8
74	Platelets Stimulate Liver Sinusoidal Endothelial Cells to Secrete Interleukin-6 During the Early Phase of Liver Regeneration in Mice. Transplantation, 2018, 102, S231.	1.0	0
75	Shotgun proteomics data on the impact of hyperglycaemia on platelet protein acetylation by aspirin. Data in Brief, 2018, 21, 2475-2481.	1.0	2
76	Effects of plasma transfusions on antithrombin levels after paediatric liver transplantation. Vox Sanguinis, 2018, 113, 569-576.	1.5	6
77	Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT): Guidance to Reduce the Risk of Intracranial Bleeding. Blood, 2018, 132, 4717-4717.	1.4	1
78	Pannexin1 Single Nucleotide Polymorphism and Platelet Reactivity in a Cohort of Cardiovascular Patients. Cell Communication and Adhesion, 2017, 23, 11-15.	1.0	10
79	TiN <i> _x </i> O <i> _y </i> coatings facilitate the initial adhesion of osteoblasts to create a suitable environment for their proliferation and the recruitment of endothelial cells. Biomedical Materials (Bristol), 2017, 12, 025001.	3.3	8
80	Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients?. American Journal of Medicine, 2017, 130, 1220.e17-1220.e22.	1.5	11
81	Accuracy and consistency of antiâ€Xa activity measurement for determination of rivaroxaban plasma levels. Journal of Thrombosis and Haemostasis, 2017, 15, 1576-1583.	3.8	21
82	Impact of a productâ€specific reference standard for the measurement of a <scp>PEG</scp> ylated <scp>rFVIII</scp> activity: the Swiss Multicentre Field Study. Haemophilia, 2017, 23, e335-e339.	2.1	20
83	Impact of rivaroxaban on point-of-care assays. Thrombosis Research, 2017, 153, 65-70.	1.7	26
84	Platelets in liver regeneration. ISBT Science Series, 2017, 12, 455-462.	1.1	8
85	Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation. Journal of Visualized Experiments, 2017, , .	0.3	3
86	Impact of (CYP3A Inhibiting) Antiretroviral Treatment on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel. Clinical Therapeutics, 2017, 39, e65.	2.5	0
87	Platelets stimulate liver sinusoidal endothelial cells to secrete interleukin-6 during the early phase of liver regeneration in mice. Journal of Hepatology, 2017, 66, S202.	3.7	1
88	Impact of pneumatic tube system transport for the monitoring of heparin therapy. Thrombosis Research, 2017, 158, 35-37.	1.7	1
89	Subthalamic nucleus deep brain stimulation for Parkinson's disease in a patient with severe haemophilia A. Haemophilia, 2017, 23, e246-e248.	2.1	2
90	A multicenter study to assess the reproducibility of antiphospholipid antibody results produced by an automated system. Journal of Thrombosis and Haemostasis, 2017, 15, 91-95.	3.8	25

#	Article	IF	CITATIONS
91	Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP)–ÂSeptember 2015. Anaesthesia, Critical Care & Pain Medicine, 2017, 36, 73-76.	1.4	66
92	Comparative Long-Term Effect of Three Anti-P2Y12 Drugs after Percutaneous Angioplasty: An Observational Study Based on Electronic Drug Adherence Monitoring. Frontiers in Pharmacology, 2017, 8, 738.	3.5	2
93	Pannexin- and Connexin-Mediated Intercellular Communication in Platelet Function. International Journal of Molecular Sciences, 2017, 18, 850.	4.1	16
94	Antiplatelet therapy: indications and limitations in the elderly population. Sang Thrombose Vaisseaux, 2017, 29, 163-167.	0.1	0
95	Antiplatelet therapy: indications and limitations in the elderly population. Hematologie, 2016, 22, 315-318.	0.0	0
96	Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Thrombosis and Haemostasis, 2016, 115, 823-825.	3.4	32
97	Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect. Frontiers in Pharmacology, 2016, 7, 494.	3.5	45
98	Anti-apolipoprotein A-1 auto-antibodies as active modulators of atherothrombosis. Thrombosis and Haemostasis, 2016, 116, 554-564.	3.4	20
99	Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach. Clinical Pharmacology and Therapeutics, 2016, 100, 295-304.	4.7	36
100	<i>TRAF3</i> Epigenetic Regulation Is Associated With Vascular Recurrence in Patients With Ischemic Stroke, 2016, 47, 1180-1186.	2.0	46
101	Effect of longâ€ŧerm adherence to clopidogrel on the VASPâ€PRI after elective coronary stent implantation: a randomized controlled study. British Journal of Clinical Pharmacology, 2016, 82, 1486-1497.	2.4	6
102	Correction of prasugrelâ€related bleeding by prophylactic transfusion of human platelets in a rabbit model. Transfusion, 2016, 56, 2618-2626.	1.6	2
103	Management of heparin-induced thrombocytopenia. Current Opinion in Hematology, 2016, 23, 462-470.	2.5	36
104	New molecular insights into modulation of platelet reactivity in aspirin-treated patients using a network-based approach. Human Genetics, 2016, 135, 403-414.	3.8	21
105	<i>PPM1A</i> Methylation Is Associated With Vascular Recurrence in Aspirin-Treated Patients. Stroke, 2016, 47, 1926-1929.	2.0	28
106	Modulation of osteoblast behavior on TiN _x O _y coatings by altering the N/O stoichiometry while maintaining a high thrombogenic potential. Journal of Biomaterials Applications, 2016, 30, 1219-1229.	2.4	5
107	Aspirin response: Differences in serum thromboxane B2 levels between clinical studies. Platelets, 2016, 27, 196-202.	2.3	10
108	Pharmacogenomics of Oral Antithrombotic Drugs. Current Pharmaceutical Design, 2016, 22, 1933-1949.	1.9	13

#	Article	IF	CITATIONS
109	Direct oral anticoagulants: a guide for daily practice. Swiss Medical Weekly, 2016, 146, w14286.	1.6	11
110	Genetic testing to identify women at risk of venous thromboembolism with contraceptive pills: Evidence or hope-based tool ?. Swiss Medical Weekly, 2016, 146, w14321.	1.6	3
111	Authors' reply to the technical comment from Joelle Michaud and Goranka Tanackovic. Swiss Medical Weekly, 2016, 146, w14383.	1.6	0
112	Lack of Effect of Platelet Transfusions and Desmopressin on Intracranial Bleeding in a Patient Receiving Ticagrelor. A & A Case Reports, 2015, 4, 169-171.	0.7	14
113	Functional role of a polymorphism in the Pannexin1 gene in collageninduced platelet aggregation. Thrombosis and Haemostasis, 2015, 114, 325-336.	3.4	34
114	Antiplatelet drugs and platelet reactivity: is it time to halt clinical research on tailored strategies?. Expert Opinion on Pharmacotherapy, 2015, 16, 449-452.	1.8	8
115	Fibrin degradation during sonothrombolysis – Effect of ultrasound, microbubbles and tissue plasminogen activator. Journal of Drug Delivery Science and Technology, 2015, 25, 29-35.	3.0	12
116	Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: Anex vivostudy. Platelets, 2015, 26, 324-330.	2.3	33
117	A focus on the role of platelets in liver regeneration: Do platelet-endothelial cell interactions initiate the regenerative process?. Journal of Hepatology, 2015, 63, 1263-1271.	3.7	75
118	Heparin-Induced Thrombocytopenia. New England Journal of Medicine, 2015, 373, 252-261.	27.0	492
119	Aspirin-mediated acetylation of haemoglobin increases in presence of high glucose concentration and decreases protein glycation. EuPA Open Proteomics, 2015, 8, 116-127.	2.5	9
120	Suspicion of heparin-induced thrombocytopenia in internal medicine: How appropriate is the ordering of anti-PF4/heparin antibody testing?. Platelets, 2015, 26, 632-637.	2.3	8
121	The Human Diabetes Proteome Project (HDPP): The 2014 update. Translational Proteomics, 2015, 8-9, 1-7.	1.2	7
122	Reply to: "The role of platelets in liver regeneration – What don't we know?― Journal of Hepatology, 2015, 63, 1538-1539.	3.7	7
123	Bilan de thrombophilie dans la maladie thromboembolique veineuse. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2015, 2015, 20-22.	0.0	0
124	Characterisation of the influences of aspirin-acetylation and glycation on human plasma proteins. Journal of Proteomics, 2015, 114, 125-135.	2.4	16
125	Evidence-Based Choice of P2Y12 Inhibitors in End Stage Renal Disease Patients: A Mini-Review. Current Drug Metabolism, 2015, 16, 97-104.	1.2	5
126	Direct oral anticoagulants: efficacy and safety in patient subgroups. Swiss Medical Weekly, 2015, 145, w14081.	1.6	13

#	Article	IF	CITATIONS
127	Human Platelets Are Internalized By Liver Sinusoidal Endothelial Cells and Enhance Secretion of EGF Transplantation, 2014, 98, 417.	1.0	1
128	Fibrinogen geneva II. Blood Coagulation and Fibrinolysis, 2014, 25, 280-282.	1.0	5
129	Refinement of the cutoff values of the HemosIL AcuStar assay for the detection of anticardiolipin and anti-beta2 glycoprotein-1 antibodies. Journal of Thrombosis and Haemostasis, 2014, 12, 2034-2037.	3.8	15
130	Role of paraoxonase-1 in CYP2C19 loss-of-function carriers. Thrombosis Research, 2014, 133, 519.	1.7	1
131	Antiplatelet Therapy: Targeting the TxA2 Pathway. Journal of Cardiovascular Translational Research, 2014, 7, 29-38.	2.4	72
132	Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. European Heart Journal, 2014, 35, 1836-1843.	2.2	16
133	Proteome Changes in Platelets After Pathogen Inactivation—An Interlaboratory Consensus. Transfusion Medicine Reviews, 2014, 28, 72-83.	2.0	80
134	Impact of high glucose concentration on aspirin-induced acetylation of human serum albumin: An in vitro study. EuPA Open Proteomics, 2014, 3, 100-113.	2.5	12
135	Sputtered titanium oxynitride coatings for endosseous applications: Physical and chemical evaluation and first bioactivity assays. Applied Surface Science, 2014, 317, 986-993.	6.1	37
136	How to manage prasugrel and ticagrelor in daily practice. European Journal of Internal Medicine, 2014, 25, 213-220.	2.2	11
137	Characterization of the platelet granule proteome: Evidence of the presence of MHC1 in alpha-granules. Journal of Proteomics, 2014, 101, 130-140.	2.4	82
138	Evaluation of the GEM®PCL Plus point-of-care device for neonatal coagulation assessment: An observational study on cord blood. Thrombosis Research, 2014, 134, 474-478.	1.7	2
139	Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. Haematologica, 2014, 99, 1387-1394.	3.5	63
140	Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013. Archives of Cardiovascular Diseases, 2013, 106, 382-393.	1.6	281
141	The Human Diabetes Proteome Project (HDPP): From network biology to targets for therapies and prevention. Translational Proteomics, 2013, 1, 3-11.	1.2	18
142	Unraveling modulators of platelet reactivity in cardiovascular patients using omics strategies: Towards a network biology paradigm. Translational Proteomics, 2013, 1, 25-37.	1.2	5
143	Thrombotic complications of myeloproliferative neoplasms: risk assessment and riskâ \in guided management. Journal of Thrombosis and Haemostasis, 2013, 11, 1215-1227.	3.8	67
144	Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping. Journal of the American Heart Association, 2013, 2, e000131.	3.7	20

#	Article	IF	CITATIONS
145	Prevalence of poor biological response to clopidogrel. Thrombosis and Haemostasis, 2012, 107, 494-506.	3.4	81
146	Poor Responsiveness to Antiplatelet Drugs in Acute Coronary Syndromes: Clinical Relevance and Management. Cardiovascular Therapeutics, 2012, 30, e41-50.	2.5	6
147	The paraoxonaseâ€1 pathway is not a major bioactivation pathway of clopidogrel <i>in vitro</i> . British Journal of Pharmacology, 2012, 166, 2362-2370.	5.4	18
148	Antiplatelet Drug Response Status Does Not Predict Recurrent Ischemic Events in Stable Cardiovascular Patients. Circulation, 2012, 125, 3201-3210.	1.6	82
149	Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 2012, 10, 1242-1251.	3.8	62
150	Platelet proteomics. Mass Spectrometry Reviews, 2012, 31, 331-351.	5.4	43
151	Aspirin for venous thromboembolism prevention and treatment: a renewal?. Polish Archives of Internal Medicine, 2012, 122, 461-463.	0.4	1
152	Platelet reactivity is a stable and global phenomenon in aspirin-treated cardiovascular patients. Thrombosis and Haemostasis, 2011, 106, 466-474.	3.4	11
153	Relationship between paraoxonaseâ€1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. Journal of Thrombosis and Haemostasis, 2011, 9, 1664-1666.	3.8	48
154	The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin. Journal of Thrombosis and Haemostasis, 2011, 9, 2109-2111.	3.8	18
155	Connexin 37 Limits Thrombus Propensity by Downregulating Platelet Reactivity. Circulation, 2011, 124, 930-939.	1.6	46
156	Impact of Genetic Polymorphisms and Drug – Drug Interactions on Clopidogrel and Prasugrel Response Variability. Current Drug Metabolism, 2010, 11, 667-677.	1.2	49
157	Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 2010, 8, 923-933.	3.8	113
158	Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. Journal of Thrombosis and Haemostasis, 2010, 8, 2614-2623.	3.8	71
159	No influence of the VAMP8 rs1010 single nucleotide polymorphism on platelet functions <i>in vitro</i> . Journal of Cellular and Molecular Medicine, 2009, 13, 601-603.	3.6	3
160	Platelet hyperreactivity and dual antiplatelet therapy: can biases be avoided?. Journal of Thrombosis and Haemostasis, 2009, 7, 363-364.	3.8	3
161	Cell-derived microparticles in haemostasis and vascular medicine. Thrombosis and Haemostasis, 2009, 101, 439-451.	3.4	359
162	Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. Future Cardiology, 2009, 5, 479-493.	1.2	24

#	Article	IF	CITATIONS
163	Intercellular Communication in Atherosclerosis. Physiology, 2009, 24, 36-44.	3.1	32
164	Acute Coronary Syndrome and its Antithrombotic Treatment: Focus on Aspirin and Clopidogrel Resistance. Current Vascular Pharmacology, 2009, 7, 198-208.	1.7	13
165	Use of the PFA-100â,,¢ closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 2008, 6, 444-450.	3.8	130
166	Impending paradoxical embolism. Annales De Cardiologie Et D'Angeiologie, 2008, 57, 234-237.	0.6	8
167	Assessing aspirin responsiveness using the Verify Now Aspirin assay. Thrombosis Research, 2008, 121, 581-582.	1.7	2
168	Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19âŽ2 allele on clopidogrel responsiveness. Thrombosis Research, 2008, 121, 463-468.	1.7	68
169	Laboratory-Defined Aspirin Resistance and Recurrent Cardiovascular Events. Archives of Internal Medicine, 2008, 168, 549.	3.8	3
170	Aspirin response variability assessed with the PFA-100 device. Thrombosis and Haemostasis, 2008, 99, 968-969.	3.4	5
171	Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. Journal of Thrombosis and Haemostasis, 2007, 5, 2153-2155.	3.8	117
172	New Antiplatelet Strategies in Atherothrombosis and Their Indications. European Journal of Vascular and Endovascular Surgery, 2007, 34, 10-17.	1.5	28
173	Subfractionation and purification of intracellular granule-structures of human platelets: An improved method based on magnetic sorting. Journal of Immunological Methods, 2007, 328, 89-96.	1.4	16
174	Identification of functional polymorphisms of the thromboxane A2 receptor gene in healthy volunteers. Thrombosis and Haemostasis, 2006, 96, 356-360.	3.4	28
175	Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood, 2006, 108, 2937-2941.	1.4	259
176	Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. Journal of Thrombosis and Haemostasis, 2006, 4, 813-819.	3.8	88
177	Plasma levels of the growth arrest-specific gene 6 product (Gas6) and antiplatelet drug responsiveness in healthy subjects. Journal of Thrombosis and Haemostasis, 2006, 4, 2283-2284.	3.8	19
178	Incidence and clinical significance of antiâ€₱F4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparinâ€induced thrombocytopenia. European Journal of Haematology, 2006, 76, 420-426.	2.2	162
179	Physiological Plasma Gas6 Levels Do Not Influence Platelet Aggregation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, e22.	2.4	17
180	Common sequence variations in the P2Y12and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets, 2006, 17, 250-258.	2.3	65

#	Article	IF	CITATIONS
181	P2Y1 gene polymorphism and ADP-induced platelet response. Journal of Thrombosis and Haemostasis, 2005, 3, 2349-2350.	3.8	12
182	Not all statins interfere with clopidogrel during antiplatelet therapy. European Journal of Clinical Investigation, 2005, 35, 476-481.	3.4	40
183	Skin necrosis is a clinical manifestation of low-molecular weight heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 2004, 91, 196-197.	3.4	11
184	The TF-603A/G gene promoter polymorphism and circulating monocyte tissue factor gene expression in healthy volunteers. Thrombosis and Haemostasis, 2004, 91, 248-254.	3.4	34
185	Tissue factor expression and P2Y12 gene polymorphism. Journal of Thrombosis and Haemostasis, 2004, 2, 1199-1200.	3.8	1
186	The factor II G20210A gene polymorphism, but not factor V Arg506Gln, is associated with peripheral arterial disease: results of a case-control study. Journal of Thrombosis and Haemostasis, 2004, 2, 1334-1340.	3.8	39
187	Prolonged treatment of massive postpartum haemorrhage with recombinant factor VIIa: case report and review of the literature. BJOG: an International Journal of Obstetrics and Gynaecology, 2004, 111, 284-287.	2.3	74
188	P2Y12 H2 haplotype is associated with peripheral arterial disease: A case controlled study. Journal of Vascular Surgery, 2004, 39, 1356.	1.1	0
189	Skin necrosis is a clinical manifestation of low-molecular weight heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 2004, 91, 196-7.	3.4	2
190	Adenosine Diphosphate–Induced Platelet Aggregation Is Associated WithP2Y12Gene Sequence Variations in Healthy Subjects. Circulation, 2003, 108, 989-995.	1.6	402
191	P2Y 12 H2 Haplotype Is Associated With Peripheral Arterial Disease. Circulation, 2003, 108, 2971-2973.	1.6	156
192	An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. Blood, 2003, 101, 1833-1840.	1.4	99
193	Autosomal-dominant giant platelet syndromes: a hint of the same genetic defect as in Fechtner syndrome owing to a similar genetic linkage to chromosome 22q11-13. Blood, 2000, 96, 3447-3451.	1.4	47
194	Dose-Dependent Inverse Relationship Between Alcohol Consumption and Serum Lp(a) Levels in Black African Males. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1075-1082.	2.4	26
195	Effect of Cardiopulmonary Bypass and Heparin on Plasma Levels of Lp(a) and Apo(a) Fragments. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1060-1065.	2.4	8
196	Apolipoprotein E polymorphism and the distribution profile of very low density lipoproteins; an influence of the E4 allele on large (Sf>60) particles. Atherosclerosis, 1998, 138, 207-215.	0.8	10
197	2.P.116 Alcohol consumption, lipoprotein(a) and hormonal status in middle-aged black African males. Atherosclerosis, 1997, 134, 140-141.	0.8	0